CHUGAI

Aiming to become a "top pharmaceutical company"

FY2013 2Q Consolidated Financial Overview (IFRS based)

CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President CFO Yoshio Itaya

July 25/26, 2013

FY2013 2Q Consolidated Financial Overview



Forward-Looking Statements

This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the "Company"). These statements reflect the Company's current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company's businesses.

FY2013 2Q Consolidated Financial Overview

CHUGAI

Summary

■ Revenues: 201.0 billion JPY (+8.4% YoY)

- Domestic sales excl. TAM (+1.0%) : continued strong growth in oncology and new products more than offset the impact from termination of Evista and the NHI price revision
- Overseas sales: approx. 30% increase due to weak yen and growth in Actemra export
- Royalties and other operating income: more than doubled driven by milestone income

Expenses

• Double-digit increase results from negative foreign exchange impact on expenses of overseas sales subsidiaries and R&D expenses

Profits

- IFRS based profits: operating profit 38.1 billion JPY (+4.7%), net income 25.3 billion JPY (+15.0%)
- Core operating profit: 38.7billion JPY (+4.9%)
- Core EPS: 46.06 JPY (+14.4%)

FY2013 2Q Consolidated Financial Overview

CHUGAI

IFRS and Core Results Jan - Jun

Billions of JPY	2013 Jan - Jun	Non-co Intangible assets and Business combinations	re items Other eliminated items	Core results 2013 Jan - Jun	Non-Core items 1. Intangible/Business combinations Amortization of intangible assets: +0.5bn JPY
Revenues	201.0			201.0	No impairment of intangible
Sales	188.8			188.8	assets No business combinations
Royalties and other operating income	12.2				2. Other eliminated items
Cost of sales	-88.3	+0.4		-87.9	Restructuring: +0.2bn JPY Environmental costs: -0.1 bn JPY
Gross profit	112.7	+0.4		113.1	Legal costs: immaterial
Operating expenses	-74.6	+0.0	+0.1	-74.4	(Billions of JPY)
Marketing and distribution	-34.1	+0.0	+0.1	-34.0	Core net income
Research and development	-34.9	+0.0	+0.1	-34.8	attributable to Chugai shareholders 25.1
General and administration	-5.6		-0.1	-5.7	
Operating profit	38.1	+0.5	+0.1	38.7	(Millions of shares)
Financing costs	-0.0			-0.0	
Other financial income (expense)	-1.2			-1.2	number of shares and equity securities
Profit before taxes	36.9	+0.5	+0.1	37.5	in issue used to
Income taxes	-11.7	-0.2	-0.0	-11.9	calculate diluted earnings per share 545
Net income	25.3	+0.3	+0.1	25.6	
Chugai shareholders	24.7	+0.3	+0.1	25.1	(JPY)
Non-controlling interests	0.5			0.5	Core EPS 46.06



Year on Year (Core)

Financial Overview Jan - Jun

(Billion JPY)	2012 Jan - J	un	2013 Jan - J	un	Growth			(Billio	on JF	PY)
Revenues	185.5	/s. Rev*.	201.0	/s. Rev*.	+15.5	+8.4%	Royalties an	d other o	pera	ating	
Sales	180.1		188.8		+8.7	+4.8%	income				+6.8
excl. Tamiflu	171.9		179.8		+7.9	+4.6%	Milestone	income i	ncre	eased	
Domestic	150.5		152.0		+1.5	+1.0%					
Export to Roche	13.4		18.4		+5.0	+37.3%	Financing co	osts			+0.0
Other overseas	8.1		9.4		+1.3	+16.0%					
Tamiflu	8.1		9.0		+0.9	+11.1%	Other financial income (exp.) Exchange gains/losses		+0.0 -3.0		
Ordinary	7.8		8.2		+0.4	+5.1%	00		+3.0		
Stockpiling	0.4		0.8		+0.4	+100.0%					
Royalties and other operating income	5.4		12.2		+6.8	+125.9%					
Cost of sales	-81.3	43.8%	-87.9	43.7%	-6.6	+8.1%		12 –Jun		2013 Jan -J	
Gross profit	104.2	56.2%	113.1	56.3%	+8.9	+8.5%	45.	1%		46.69	
Operating expenses	-67.3	36.3%	-74.4	37.0%	-7.1	+10.5%	Avorage	exchan	no re	oto (ID	
Operating profit	36.9	19.9%	38.7	19.3%	+1.8	+4.9%	Average	2012			1)
Financing costs	-0.0		-0.0		+0.0	0.0%		Jan -Ji			-Jun
Other financial income (expense)	-1.2		-1.2		+0.0	0.0%	CHF	85.8			1.94
Taxes	-13.3		-11.9		+1.4	-10.5%	EUR	103.3	9	125	5.33
Net income	22.3	12.0%	25.6	<mark>12.7%</mark>	+3.3	14.8%	*Revenues				

FY2013 2Q Consolidated Financial Overview




FY2013 2Q Consolidated Financial Overview

Year on Year

Sales (excl. Tamiflu) Jan - Jun





FY2013 2Q Consolidated Financial Overview

CHUGAI

Tamiflu Sales Performance

					F	iscal Term	Sales					
(Billion JPY)		FY20	FY2009.12		FY2010.12		FY2011.12		12.12	FY2013.12	Seasonal	Cases per sentinel*
		Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Sales	(millions)
	2008-09	11.0									16.7	1.27
	2009-10		25.2	1.4							26.6	2.02
Ordinary	2010-11				0.2	4.1					4.3	1.26
	2011-12						1.3	7.8			9.1	1.63
	2012-13								2.4	8.2	10.6	1.11
Oı	dinary	36.2	(+29.1)	1.6	(-34.6)	5.4	(+3.8)	10.2	(+4.8)			
	2008-09	14.4									15.5	
Govt.	2009-10		25.6	10.6							36.2	
Stockpile	2010-11				5.9	0.5					6.4	
etc.	2011-12						2.8	0.4			3.2	
	2012-13								1.5	0.8	2.3	
Govt. S	tockpile etc.	40.0	(+38.7)	16.6	(-23.4)	3.3	(-13.3)	1.9	(-1.4)			
		25.4	50.8	12.0	6.1	4.6	4.1	8.1	3.9	9.0		
	Total	76.2	(+67.8)	18.2	(-58.0)	8.7	(-9.5)	12.0	(+3.3)			

*Total patient number of the controlled samples in the infectious Diseases Weekly Report, period between late October and mid-April (between early July 2009 and mid-March 2010 for 2009/2010), published by Japan's National Institute of Infectious Diseases.


FY2013 2Q Consolidated Financial Overview

Year on Year (Core)

Operating Profit Jan - Jun



(Billion JPY)



(Billion JPY)	2012	2013 Jan - Jun	Growth				
Revenues	185.5	201.0	+15.5				
Cost of sales	-81.3	-87.9	-6.6				
Gross profit	104.2	113.1	+8.9				
Sales	98.8	100.9	+2.1				
Royalties, etc.	5.4	12.2	+6.8				
Marketing and distribution	-32.2	-34.0	-1.8				
Research and development	-31.1	-34.8	-3.7				
General and administration	-4.0	-5.7	-1.7				
Operating profit	Operating profit 36.9 38.7						
Increase in gross profit from sales +2.1 Increase in new products and Actemra overseas							
Increase in royalties ar	nd other oper	ating income	e +6.8				
Increase in marketing and distribution -1.8 Negative foreign exchange impact on expenses of							
overseas sales subsidiaries, etc Increase in research and development -3.7 Negative foreign exchange impact and full-fledged							
•	operation of CPR*, etc Increase in general and administration -1.7						

*Chugai Pharmabody Research: antibody research center in Singapore

Year on Year (Core)

Financial Overview Apr - Jun

(Billion JPY)	2012 Apr - J	un	2013 Apr - J	un	Grow	/th	(Billion JPY)
Revenues	95.2	/s. Rev*.	110.6	/s. Rev*.	+15.4	+16.2%	Royalties and other operating income
Sales	93.3		101.8		+8.5	+9.1%	+6.9
excl. Tamiflu	93.0		101.1		+8.1	+8.7%	Milestone income increased
Domestic	82.4		83.2		+0.8	+1.0%	Expenses -5.1
Export to Roche	6.6		13.3		+6.7	+101.5%	
Other overseas	4.1		4.6		+0.5	+12.2%	M&D -1.2
Tamiflu	0.3		0.7		+0.4	+133.3%	FX impact, promotions for new products, etc
Ordinary	0.3		0.7		+0.4	+133.3%	
Stockpiling	-		-		-	-	R&D -3.0
Royalties and other operating income	1.9		8.8		+6.9	+363.2%	FX impact, CPR, facility-related expenses, etc
Cost of sales	-41.9	44.0%	-47.3	42.8%	-5.4	+12.9%	G&A -1.0
Gross profit	53.2	55.9%	63.3	57.2%	+10.1	+19.0%	Increase in activities
Operating expenses	-34.5	36.2%	-39.6	35.8%	-5.1	+14.8%	
Operating profit	18.8	19.7%	23.6	21.3%	+4.8	+25.5%	
Financing costs	-0.0		-0.0		+0.0	-	Cost of sales ratio vs. Sales
Other financial income (expense)	-0.9		-0.2		+0.7	-77.8%	2012 2013
Taxes	-6.6		-7.3		-0.7	+10.6%	Apr – Jun Apr – Jun 44.9% 46.5%
Net income	11.3	11.9%	16.2	<mark>14.6%</mark>	+4.9	43.4%	*Revenues



FY2013 2Q Consolidated Financial Overview

FY2013 2Q Consolidated Financial Overview

vs. Forecast (Core)

Financial Overview Jan - Jun



	Actual	Forecast	on Jan 30	2012
(Billion JPY)	2013 Jan - Jun	2013 Jan - Dec	Progress	Progress*
Revenues	201.0	416.0	48.3%	48.0%
Sales	188.8	394.3	47.9%	48.0%
excl. Tamiflu	179.8	385.5	46.6%	47.3%
Domestic	152.0	329.3	46.2%	46.9%
Export to Roche	18.4	40.6	45.3%	52.3%
Other overseas	9.4	15.6	60.3%	48.5%
Tamiflu	9.0	8.8	102.3%	67.5%
Royalties and other operating income	12.2	21.7	56.2%	47.8%
Cost of sales	-87.9	-183.2	48.0%	48.6%
Gross profit	113.1	232.8	48.6%	47.5%
Operating expenses	-74.4	-155.3	47.9%	46.8%
Operating profit	38.7	77.5	49.9%	48.8%
EPS (JPY)	46.06	92.57	49.8%	47.0%

*Jan - Jun progress versus Jan - Dec

FY2013 2Q Consolidated Financial Overview

vs. Forecast

(Roche) Roche Group

Domestic Sales (excl. Tamiflu) Jan - Jun

	Actual	Forecast	on Jan 30	2012
(Billion JPY)	2013	2013	Progress	Progress*
	Jan - Jun	Jan - Dec	T TOGICOO	T TOGICOO
Domestic sales excl. Tamiflu	152.0	329.3	46.2%	46.9%
Oncology	78.7	175.4	44.9%	46.4%
Avastin	34.8	76.6	45.4%	45.2%
Herceptin	14.4	30.4	47.4%	47.0%
Xeloda	5.5	13.9	39.6%	47.7%
Tarceva	4.6	11.0	41.8%	47.4%
Bone and Joint	27.5	54.3	50.6%	45.7%
Actemra	9.1	19.1	47.6%	46.2%
Edirol	6.4	11.0	58.2%	32.9%
Renal	22.5	52.0	43.3%	47.6%
Mircera	9.8	28.2	34.8%	42.1%
Epogin	5.2	8.6	60.5%	53.1%
Transp., Immun., Infectious	9.2	18.1	50.8%	48.3%
Pegasys	2.8	5.7	49.1%	49.3%
Copegus	0.7	1.2	58.3%	50.0%
Others	14.2	29.6	48.0%	49.8%

*Jan - Jun progress versus Jan - Dec

vs. Forecast (Core)


ACCEL 15

CHUGAI

Impact from Foreign Exchange

(Billion JPY)	FX impact Jan - Jun (vs. Forecast on Jan. 30)	
	+2.4	
Revenues	Actemra (Export) Neutrogin (Overseas)	+1.3 +0.6
	Other products, royalties, etc	+0.5
Cost of sales Operating expenses	Cost of sales Expenses	-2.2 -0.7
Operating Profit	-0.5	

FX rate to the JPY	1CHF	1EUR
Assumption Jan – Dec (as of Jan. 30)	95.00	115.00
Actual Jan – Jun avg.	101.94	125.33
Reference Actual Jan – Jun avg. (2012)	85.82	103.39



11

vs. 2012 Year End

Balance Sheet Items

(Billion JPY)	2013 Dec	2013 Jun	Change
Trade accounts receivable	115.7	109.2	- 6.5
Inventories	108.4	114.1	+ 5.7
Trade accounts payable	-41.8	-33.6	+ 8.2
Other net working capital	-24.4	-18.6	+ 5.8
Net working capital	157.9	171.1	+ 13.2
Property, plant and equipment	143.1	139.9	- 3.2
Intangible assets	6.5	7.2	+ 0.7
Other long-term assets -net	0.4	-2.1	- 2.5
Long-term net operating assets	150.0	145.0	- 5.0
Net operating assets	307.9	316.1	+ 8.2
Debt	-0.3	-0.3	0.0
Marketable securities	116.5	122.9	+ 6.4
Cash and cash equivalents	95.4	100.5	+ 5.1
Net cash	211.7	223.2	+ 11.5
Other non-operating assets - net	9.6	9.6	0.0
Net non-operating assets	221.3	232.7	+ 11.4
Total net assets	529.2	548.8	+ 19.6
Total net assets	529.2	548.8	+ 19.6
Total assets	645.3	654.5	+ 9.2
Total liabilities	-116.2	-105.7	+ 10.5

Net working capital +13.2Trade accounts receivable Seasonal change -6.5 +5.7Inventories Increase in demand and in safety stocks to ensure stable supply, and FX impact Trade accounts payable +8.2Procurement timing Long-term net operating assets -5.0 Property, plant and equipment -3.2 Net cash +11.5Equity ratio attributable to Chugai shareholders +1.8%pts 2013 Jun 83.6%

2012 Dec 81.8%

Other net working capital: accrued payable, accrued expenses etc

Other long-term assets: long term prepaid expenses, deferred income etc.

Other long-term non-operating assets: deferred income tax assets, accrued corporate tax.




FY2013 2Q Consolidated Financial Overview

FY2013 2Q Consolidated Financial Overview

CHUGAI

Actual 2013

Net Cash Jan - Jun



FY2013 2Q Consolidated Financial Overview

Year on Year

Free Cash Flow Jan - Jun



(Billion JPY)	2012 Jan-Jun	2013 Jan-Jun	Change
Operating profit - IFRS basis	36.4	38.1	+1.7
Depreciation and impairment of PPE	6.4	7.2	+0.8
Amortization and impairment of intangible assets	0.4	0.5	+0.1
Other cash adjustment on operating profit	-1.7	1.3	+3.0
Operating cash flow after adjustments	41.5	47.2	+5.7
Increase (-) / decrease in trade accounts receivable	11.7	6.8	-4.9
Increase (-) / decrease in inventories	4.7	-6.1	-10.8
Increase / decrease (-) in trade accounts payable	9.4	-8.4	-17.8
Other change in net working capitals	-3.0	-1.9	+1.1
Total increase (-) / decrease in net working capital	22.8	-9.7	-32.5
Investment in PPE*	-7.1	-6.5	+0.6
Investment in intangible assets	-0.3	-0.4	-0.1
Total investment	-7.4	-6.9	+0.5
Operating free cash flow	56.9	30.6	-26.3
as % of revenues	30.7%	15.2%	-15.5%pts
Treasury activities	-0.1	0.5	+0.6
Tax paid	-13.9	-11.9	+2.0
Dividends paid	-11.3	-11.4	-0.1
Free cash flow	31.5	7.8	-23.7
Transaction in own equity instruments	-0.0	0.6	+0.6
Net effect of currency translationactions on net cash	-0.3	3.1	+3.4
Net change in net cash	31.2	11.5	-19.7

Treasury activities: interest income/expenses, foreign exchange gains/losses etc.

*Property, plant and equipment

Operating cash flow after ac	ljustments +5.7
Milestone income increa	sed
Total increase (-) / decrease capital	e in net working
	-32.5
Increase in procurement	payments
Increase (-) / decrease ir	
	-10.8
Increase / decrease (-) ir payable	n trade accounts -17.8
Total investment	+0.5
Operating free cash flow	
	-26.3
Increase in procurement increase in demand and ensure stable supply, and	in safety stocks to
Operating free cash flow as	% of revenues -15.5%pts
Revenues	+15.5

Revenues

CHUGAI

Aiming to become a "top pharmaceutical company"

Overview of Development Pipeline

CHUGAI PHARMACEUTICAL CO., LTD. Senior Vice President Head of Project & Lifecycle Management Unit Yutaka Tanaka

July 25/26, 2013

Overview of Development Pipeline



Projects under Development (as of 25 July, 2013)

	Phase I	Phase II	Phase III	Filed
Oncology	CIF/RG7167 (Japan/overseas) - solid tumors CKI27/RG7304 (Japan/overseas) - solid tumors PA799 (overseas) - solid tumors RG7414/parsatuzumab - solid tumors RG7321/pictilisib - solid tumors★	RG3502 /trastuzumab emtansine - GC (PII/III) GC33/RG7686 - LC RG340/Xeloda - aGC AF802/RG7853 (Japan/overseas) - NSCLC (PI/II) RG7204/vemurafenib - melanoma (PI/II)★	RG1273/Perjeta - aBC - GC★ RG435/Avastin - aBC RG3638/onartuzumab - NSCLC GA101 (RG7159) /obinutuzumab - NHL	RG435/Avastin - OC RG3502 /trastuzumab emtansine - BC

Letters in orange: in-house projects *****: Projects with advances in stages since 25 April, 2013

Overview of Development Pipeline



Projects under Development (as of 25 July, 2013) Roche Roche Group

	Phase I	Phase II	Phase III	Filed
Bone & Joint			RG484/Bonviva (oral) - osteoporosis NRD101/Suvenyl - enthesopathy	
Autoimmune	- RA - systemic sclerosis - giant cell arteritis		MRA/Actemra (overseas) - giant cell arteritis★	MRA/Actemra (overseas) - RA (sc)
CNS	RG1450/gantenerumab - alzheimer's disease RG1577 - alzheimer's disease★	RG7090 - major depressive disorder	RG1678/bitopertin - schizophrenia	
Others	RG3637/lebrikizumab (overseas) - asthma CIM331 - atopic dermatitis ACE910 - hemophilia A RG7652 (overseas) - hyperlipidemia URC102 (South Korea) - gout★			CSG452/tofogliflozin - Type 2 diabetes★★

Letters in orange: in-house projects *****: Projects with advances in stages since 25 April, 2013 ★: The applications for approval were filed by Sanofi K.K. and Kowa Company, Ltd., respectively.

Overview of Development Pipeline



Development Status - Oncology Field



RG1415 / Tarceva[®] :

 Indication: Chemotherapy-Naïve, Unresectable, Recurrent/Advanced Non-Small Cell Lung Cancer (NSCLC) with *EGFR* Mutations Approved in June 2013



RG1273 / Perjeta[®] :

- Indication: HER2-Positive Inoperable or Recurrent Breast Cancer
 Approved in June 2013
- Expected Indication: Gastric Cancer Started Global P3 in July 2013



RG435 / Avastin[®] :

 Indication: Malignant Glioma Approved in June 2013

Overview of Development Pipeline



Development Status - Oncology Field



RG597 / Herceptin[®] :

Indication: Weekly Dosage with Chemo-Therapy for HER2 Positive Adjuvant Breast Cancer Approved in June 2013



RG7321 / GDC-0941 / pictilisib (PI3K inhibitor) : Expected Indication: Solid Tumors Started P1 in June 2013



RG7446 / MPDL3280A (anti-PD-L1 MAb) : Expected Indication: Solid Tumors In preparation to start P1 in the second half of 2013

Overview of Development Pipeline



Development Status - Primary Field

- RG484 / Bonviva® Injection :
 - Indication: Osteoporosis Approved in June 2013



Inlicensed

MRA / Actemra[®] :

- Indication: Polyarticular Juvenile Idiopathic Arthritis (pJIA) Approved in April 2013 (FDA) Approved in June 2013 (EMA)
- Subcutaneous Injection Formulation Indication: Rheumatoid Arthritis Launched in May 2013 (Japan)
- Expected Indication: Giant Cell Arteritis Started P3 in July 2013 (overseas)
- Expected Indication: Systemic Sclerosis Started P2 in March 2012 (overseas)

Overview of Development Pipeline



Development Status - Primary Field



CSG452 / tofogliflozin :

Expected indication: Type 2 diabetes The applications for approval were filed by Sanofi K.K. and Kowa Company, Ltd., respectively in April 2013



RG1577 (MAO-B inhibitor) :

Expected indication: Alzheimer's disease Started P1 in May 2013



URC102 (URAT1 inhibitor) :


Expected Indication: Gout Started P1 in June 2013 (South Korea) Co-development with JW Pharmaceutical Corporation

Overview of Development Pipeline



Projected Submissions (Post PoC products and NMEs)

Seamless filings every year




* Overseas brand name

** The applications for approval were filed by Sanofi K.K. and Kowa Company, Ltd., respectively.

Overview of Development Pipeline



RG7321 (PI3K inhibitor) - Mode of Action




- PI3K transmits intracellular signaling from the receptor through the PI3K-AKT-mTOR pathway
- PI3K participates in growth and invasion of cancer cells, and acquisition of resistance to anticancer drugs^{1, 2)}
- RG7321 is a novel small-molecule anti-cancer agent with potent and selective PI3K inhibitory activity.
 - Liu P et al., Nat Rev Drug Discov 2009
 Berns K et al., Cancer Cell 2007

PI3K: Phosphoinositide 3-kinase AKT (PKB): Protein kinase B mTOR: mammalian target of rapamycin

Overview of Development Pipeline



RG7446/MPDL3280A (anti-PD-L1 MAb) - Mode of Action Roche Group



T cell attacks tumor cells as non-self antigens.

PD-L1 expression is induced by stimulation of IFNγ, or expressed by activation of oncogenic pathway of the tumor itself. T cell will not attack the tumor cell due to induced immune tolerance by negative signal of PD-1/PD-L1 pathway.


Overview of Development Pipeline



RG7446/MPDL3280A (anti-PD-L1 MAb) - Mode of Action Revenue Group

T cell


TCR





Binding of PD-L1 to PD-1 and B7.1 induces suppressive signals and negatively regulates T cell immune responses.

Binding of MPDL3280A to PD-L1 exerts anti-tumor effects through inhibition of the PD-L1 pathway, thereby enabling antitumor T cell responses.



Binding of aPD-1 MAb to PD-1 on T cells inhibits PD-1 inhibition, but not **B7.1** inhibition. Normal immune homeostasis mediated by PD-L2 is also disrupted.




RG1577 (MAO-B inhibitor) - Mode of Action

- MAO-B is abundant in astrocytes and some neurons in human brain
- MAO-B produces reactive oxygen species associated with breakdown of the substrates
- Expression of MAO-B is increased in patients with Alzheimer's disease (AD) compared to healthy adults (Control).

MAO-B: monoamine oxidase B substrate: phenylethylamine, dopamine

Inhibition of MAO-B in AD is expected to have therapeutic effects on cognition through neuroprotection by reducing reactive oxygen species, and improvement on motivation (reduced apathy) and mood due to increased substrate levels.




Overview of Development Pipeline



CIM331 (anti-IL-31R MAb) - Mode of Action

To be presented at EADV (European Academy of Dermatology and Venereology) in October 2013


- Interleukin-31 (IL-31) is involved in pruritus in atopic dermatitis (AD)
- CIM331 inhibits IL-31 from binding to the receptor, and is expected to suppress the itching and to improve dermatitis by blocking the itchscratch-cycle



Overview of Development Pipeline



URC102 (URAT1 inhibitor) - Mode of Action



- URAT1 is an essential molecule that mediates the reabsorption of uric acid on the lumen side of the proximal tubule
- URC102 promotes the excretion of uric acid by selectively inhibiting URAT1
- Consequently, URC102 potently decreases serum uric acid

URAT1: urate transporter 1

Update on the Development Requests for Unapproved Drugs/Indications



- Review Committee of Development Request for Unapproved Drugs/Indication
 - Nine indications of 8 products have been approved, out of 10 indications (including additional dosages and administrations) of 8 products officially requested by MHLW to develop at the 1st round
 - Status of products remaining from the 1st round (Avastin) and 3 indications of the 3 products are shown below

	Product	Indication	Current Situation
1st round requests	Avastin	Ovarian cancer	Filed on 5 Oct. 2012
2nd round requests	Avastin	Recurrent glioblastoma	Approved for malignant glioma on 14 June 2013
	Herceptin	Weekly dosage with chemo- therapy for HER2 positive adjuvant breast cancer	Approved on 14 June 2013
	Cellcept	Lupus nephritis	Submitted company opinion and waiting for its evaluation by the committee

Contacts: Corporate Communications Dept.

Media Relations Group

Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607 e-mail: pr@chugai-pharm.co.jp

Hitoshi Aikawa, Koichi Kawahara, Hiroshi Araki, Sachiyo Yoshimura

Investor Relations Group

Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607 e-mail: ir@chugai-pharm.co.jp

Kae Miyata, Takayuki Sakurai, Yusuke Tokita, Shingo Kumagai